GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...

The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has ...

Super-speciality diagnostics chain Neuberg Diagnostics is in advanced stages of picking up a controlling stake in a ...

Latozinemab failure, with Nivisnebart Phase 2 data as the next key catalyst. Click here to read more about ALEC stock.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved pharma major GSK’s Exdensur (depemokimab), the first twice-yearly biological medicine for use as an add-on treatment for ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.

In this video, Jonathan A. Bernstein, MD, discusses an American College of Allergy, Asthma & Immunology Annual Scientific ...